AN-788

Last updated

AN-788
Clinical data
Other namesAN788; NSD-788; NSD788; IP-2018; IP2018
Drug class Monoamine reuptake inhibitor; Serotonin–dopamine reuptake inhibitor
Identifiers
CAS Number

AN-788, also known as NSD-788 and IP-2018, is an experimental drug which was originated by NeuroSearch and is under development by Saniona for the treatment of major depressive disorder. [1] [2] [3] [4] It was also under development for anxiety disorders, but development for this indication was discontinued. [1] The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI). [1] [3] [4] As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder. [5] As of September 2022, no recent development has been reported for major depressive disorder, but the drug is now in phase 2 cinical trials for erectile dysfunction. [1]

See also

References

  1. 1 2 3 4 "Initiator Pharma". 8 November 2018.
  2. ↑ "Delving into the Latest Updates on IP-2018 with Synapse". Synapse. 1 November 2024. Retrieved 2 November 2024.
  3. 1 2 Shao L, Li W, Xie Q, Yin H (February 2014). "Triple reuptake inhibitors: a patent review (2006 - 2012)". Expert Opinion on Therapeutic Patents. 24 (2): 131–154. doi:10.1517/13543776.2014.859676. PMID   24289044. S2CID   1825304.
  4. 1 2 Bang-Anderssen B, Bøgesø KP, Kehler J, Sánchez C (16 December 2016). "New Trends in Antidepresent Drug Research". In Ecker GF, Clausen RP, Sitte HH (eds.). Transporters as Drug Targets. Wiley. pp. 36–. ISBN   978-3-527-67951-5.
  5. ↑ "Initiator Pharma signs option agreement for Phase 2 ready drug candidate". News Powered by Cision. 8 November 2018. Retrieved 2022-02-08.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.